Member Info for HereKittyKitty

Defo

They’ve booked their delivery slots & are filling up the van with their purchases right now while the offer is on

There’s an Ocado just for them to 😁

At these levels we are talking multipliers so the lower we get to buy the better when it kicks in on significant news as 25x is much better than 10 😇😂🤪

BOING❗️

Be careful with your short to - losses could be much worse there 🔥

🔥 🔥 🔥 🔥 🔥

Up 🎈 Up 🎈 Up 🎈

Fire up the Barbie tomorrow folks 🔥 🥩 🌭

There are a few decent buys going through ….

Https://x.com/coughlin582/status/1797619192352711163?s=46&t=rZBJsvTL3ouQQ-g4EQCmcA

I smell lots of barbecued sausages

They will need to shake this so maybe a BOO buyout with IPO funds isn't out of the question

https://www.dailymail.co.uk/sciencetech/article-13468265/Shein-childrens-clothes-toxic-forever-chemicals.html#:~:text=Clothing%20and%20accessories%20sold%20by,linked%20to%20cancer%20and%20autism.

Not with these headlines https://www.dailymail.co.uk/sciencetech/article-13468265/Shein-childrens-clothes-toxic-forever-chemicals.html#:~:text=Clothing%20and%20accessories%20sold%20by,linked%20to%20cancer%20and%20autism.

Just sit and wait as potential multipliers to be realised here for patient folks who build their position

I'd rather see another 10x climb vs a cheeky 15%

Nice in the job description

Avacta’s lead pre|CISIONTM candidate, AVA6000, delivers the chemotherapeutic drug Doxorubicin directly to the tumour microenvironment. In the ongoing Phase I clinical trial, significant anti-tumour activity has been observed in some patients, while some others have exhibited stable disease. The drug also exhibited reduced toxicities as compared with standard dose Doxorubicin, and further clinical development is ongoing with the aim to provide benefit to patients. This data is described on a recent poster: https://avacta.com/wp-content/uploads/2024/04/Banerji-et-al-2024-AVA6000-AACR_final.pdf

Pipeline

In addition to being in the clinic with its lead pre|CISIONTM targeted chemotherapy programme, Avacta also has a strong pre-clinical pipeline of both Affimer® and pre|CISIONTM oncology candidates. This includes different drug warheads as well as different formats to target the drug to the tumour in a highly specific manner.

200-225 looks reasonably achievable IMHO and consensus broker is 250 high end but averages around 223

Save yourself from a load of losses before the 🔥 begins

🏎️ 💨 💨 💨

Rarely seen a share drift so aimlessly in an direction for such as sustained period

Do DARK would definitely have shot up even more on that - much higher than the current offer I would say 🤔

8% broken 💥

Broke well through 7% so what's going on ...